With regard to licensing its products, and in a similar approach to partnering, DermaGen is willing to draw up licensing agreements with interested partners after successful PoC have been completed with relevant product candidates.
The following key factors have been identified to enable successful licensing of DermaGen products:
- Efficient anti-microbial effect
- Complement to present treatments
- Unmet medical need
- Minimized product resistance
- Intellectual protection
To discuss licensing opportunities, please contact:
Dr. Jan Alenfall, CEO
Phn: +46 (0) 46 192 197
Mob: +46 (0) 709 315 115
E-mail: jan.alenfall@dermagen.se